Dimensional Fund Advisors LP trimmed its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 70.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 35,666 shares of the biotechnology company's stock after selling 86,214 shares during the period. Dimensional Fund Advisors LP's holdings in Arrowhead Pharmaceuticals were worth $671,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in ARWR. Norges Bank bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth approximately $38,622,000. Edgestream Partners L.P. purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter worth approximately $2,264,000. Wealthfront Advisers LLC purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter worth approximately $2,060,000. Marshall Wace LLP bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $1,629,000. Finally, King Luther Capital Management Corp purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at $1,447,000. 62.61% of the stock is owned by institutional investors.
Arrowhead Pharmaceuticals Stock Performance
Shares of ARWR traded up $0.55 on Tuesday, reaching $16.29. The company's stock had a trading volume of 1,940,733 shares, compared to its average volume of 1,487,202. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $30.41. The stock has a market capitalization of $2.25 billion, a P/E ratio of -3.15 and a beta of 0.89. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The stock's 50 day simple moving average is $13.30 and its two-hundred day simple moving average is $17.76.
Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The business had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same period in the previous year, the firm earned ($1.02) EPS. Research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.
Insider Activity at Arrowhead Pharmaceuticals
In related news, CEO Christopher Richard Anzalone sold 51,425 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the transaction, the chief executive officer now owns 4,062,377 shares of the company's stock, valued at approximately $61,220,021.39. This represents a 1.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 275,880 shares of company stock worth $4,034,037. 4.30% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
ARWR has been the subject of several recent analyst reports. Chardan Capital restated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. StockNews.com upgraded Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, May 14th. HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. Royal Bank of Canada reaffirmed an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Finally, Citigroup reduced their price target on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $42.13.
Check Out Our Latest Report on ARWR
Arrowhead Pharmaceuticals Company Profile
(
Free Report)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Further Reading
Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.
While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
